Iovance Biotherapeutics

OverviewSuggest Edit

Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. The Company's lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, Lion's TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers.

TypePublic
Founded2013
HQSan Carlos, US
Websiteiovance.com

Latest Updates

Employees (est.) (Dec 2019)148(+69%)
Job Openings26
Revenue (FY, 2018)$0
Share Price (Sept 2020)$35.3 (+12%)
Cybersecurity ratingCMore

Key People/Management at Iovance Biotherapeutics

Iain Dukes

Iain Dukes

Chairman of the Board
Joseph Wypych

Joseph Wypych

Vice President of Manufacturing
Maria Fardis

Maria Fardis

President & Chief Executive Officer
Ryan Maynard

Ryan Maynard

Director
Frederick G. Vogt

Frederick G. Vogt

General Counsel
Michael C. Swartzburg

Michael C. Swartzburg

Vice President, Finance
Show more

Iovance Biotherapeutics Office Locations

Iovance Biotherapeutics has offices in San Carlos, New York, Philadelphia and Tampa
San Carlos, US (HQ)
999 Skyway Rd #150
New York, US
112 W 34th St
Philadelphia, US
4747 S Broad St #120
Philadelphia, US
Crescent Dr
Tampa, US
3802 Spectrum Blvd #206
Show all (5)

Iovance Biotherapeutics Financials and Metrics

Iovance Biotherapeutics Revenue

USD

Net income (Q2, 2020)

(63.0m)

EBIT (Q2, 2020)

(63.6m)

Market capitalization (14-Sept-2020)

5.2b

Closing stock price (14-Sept-2020)

35.3

Cash (30-Jun-2020)

160.6m

EV

5.0b
Iovance Biotherapeutics's current market capitalization is $5.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

12.4m25.6m21.3m28.4m40.8m

R&D expense

1.8m1.7m1.3m2.7m15.5m28.0m71.6m99.8m166.0m

Operating expense total

1.8m1.7m1.3m2.7m27.9m53.6m92.9m128.3m206.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

2.8m7.3m10.5m4.3m3.9m4.6m7.0m6.8m7.1m9.1m10.9m10.0m13.9m14.4m

R&D expense

886.0k270.0k250.0k270.0k250.0k250.0k302.7k361.2k353.9k2.0m4.1m5.0m4.2m4.5m8.5m16.6m19.7m17.8m19.9m24.6m27.9m30.9m39.3m41.6m57.0m49.3m

Operating expense total

886.0k270.0k250.0k270.0k250.0k250.0k302.7k361.2k353.9k2.0m4.1m5.0m7.0m11.7m19.0m20.9m23.6m22.3m26.9m31.4m35.1m40.0m50.2m51.6m70.8m63.6m
USDQ2, 2011

Financial Leverage

-0.3 x
Show all financial metrics

Iovance Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Iovance Biotherapeutics Online and Social Media Presence

Embed Graph

Iovance Biotherapeutics News and Updates

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock

SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today annou…

Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

SAN CARLOS, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commercialize an antibod…

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to present at the followin…

Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business

PHILADELPHIA, May 31, 2019 /PRNewswire/ -- Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, has expanded its relationship with WuXi AppTec's Advanced Therapies Business Unit (WuXi...

Iovance Biotherapeutics to Participate in Upcoming Conferences in June

SAN CARLOS, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to participate in the follow…

Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy

SAN CARLOS, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (FDA) ha…
Show more

Iovance Biotherapeutics Blogs

Iovance Biotherapeutics to Participate in Upcoming Conferences in May

Iovance Biotherapeutics to Participate in Upcoming Conferences in May Content Import Thu, 06/27/2019 - 13:50 Iovance Biotherapeutics to Participate in Upcoming Conferences in May May 2, 2019 at 7:00 AM EDT This release is a backfill from a News Wire …

Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors

Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors Content Import Thu, 06/27/2019 - 13:50 Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors June 11, 2019 at 4:01 AM EDT This release is a backfill…

Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products

Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products Content Import Thu, 06/27/2019 - 13:50 Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Pr…
Show more

Iovance Biotherapeutics Frequently Asked Questions

  • When was Iovance Biotherapeutics founded?

    Iovance Biotherapeutics was founded in 2013.

  • Who are Iovance Biotherapeutics key executives?

    Iovance Biotherapeutics's key executives are Iain Dukes, Joseph Wypych and Maria Fardis.

  • How many employees does Iovance Biotherapeutics have?

    Iovance Biotherapeutics has 148 employees.

  • Who are Iovance Biotherapeutics competitors?

    Competitors of Iovance Biotherapeutics include LIDDS, Incuron and Cleara Biotech.

  • Where is Iovance Biotherapeutics headquarters?

    Iovance Biotherapeutics headquarters is located at 999 Skyway Rd #150, San Carlos.

  • Where are Iovance Biotherapeutics offices?

    Iovance Biotherapeutics has offices in San Carlos, New York, Philadelphia and Tampa.

  • How many offices does Iovance Biotherapeutics have?

    Iovance Biotherapeutics has 5 offices.